Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer...

Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific
Officer of Global Bioanalytical Services
-New head of global bioanalytical services brings 15 years of industry
experience to Covance-

PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- Covance Inc. today announced
that Steven M. Michael, Ph.D. has joined the company as vice president and
chief scientific officer of global bioanalytical services. With 15 years of
pharmaceutical industry experience, including bioanalytical research,
translational research, and talent development, Dr. Michael will lead
scientific, marketing, and business development strategy for Covance's
bioanalytical services.

Dr. Michael joins Covance from Pfizer Global Research and Development where he
served as executive director of bioanalytical research in Worldwide
Pharmacokinetics, Dynamics & Metabolism. As a member of the executive
leadership team, he provided strategic leadership for the Worldwide
Pharmacokinetics, Dynamics & Metabolism group and led the regulated
bioanalytical support of the Pfizer human health portfolio. Dr. Michael's
experience also includes drug discovery, drug development, and research
technology with focus on bioanalytical research, translational research,
biomarkers, and leadership development.

Dr. Michael received a doctorate in analytical chemistry from the University
of Michigan. He is a member of the American Society of Mass Spectrometry and
the American Association of Pharmaceutical Scientists and has been published
in various scientific publications, including Analytical Chemistry, Journal of
Pharmaceutical and Biomedical Analysis, and International Journal of Mass
Spectrometry and Ion Process.

Offering global flexible capacity and more than 350 bioanalytical scientists
with more than 2,600 years of combined industry experience, Covance's
bioanalytical services group develops and validates more than 550 methods
every year to support drug development from discovery through Phase IV.

About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1.7 billion, global operations in more than 25
countries, and more than 9,800 employees worldwide. Information on Covance's
products and services, recent press releases, and SEC filings can be obtained
through its website at www.covance.com.

Statements contained in this press release, which are not historical facts,
are forward-looking statements pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All such forward-looking
statements including the statements contained herein regarding anticipated
trends in the Company's business are based largely on management's
expectations and are subject to an qualified by risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, without
limitation, competitive factors, outsourcing trends in the pharmaceutical
industry, levels of industry research and development spending, the Company's
ability to continue to attract and retain qualified personnel, the fixed price
nature of contracts or the loss of large contracts, and other factors
described in the Company's filings with the Securities and Exchange
Commission.

SOURCE Covance Inc.

Media Relations, +1-609-452-4275; Investor Relations: +1-609-452-4807